MarginsXMarginsX
Home › Markets › OTLC

Oncotelic Therapeutics, Inc. (OTLC)

OTLC is quoted over the counter, not listed on an exchange. Oncotelic Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.0134
+34.0% on the day
1-year return
-85.1%
Market cap
$6.1M
Nano cap. From the Nov 16, 2026 close × 457.5M shares (10-Q cover page, Aug 13, 2026)
P/E and P/S
0.0× · No revenue line filed
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerOTLC, quoted over the counter
SEC CIK0000908259
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressAguora Hills, CA
Incorporated inDE

Warning signs

Cash runway
1.5 months
$186K cash at June 30, 2026
Share count, 1 year
+5.2%
2025-08-13 to 2026-08-13 · +14.9% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$38K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of this filing."
10-Q 2026-08-13
Cash and burn$186K cash; operating cash flow -$381K a quarter.Report 2026-06-30
Shares outstanding457,512,796 (2026-08-13); 434,929,966 a year earlier; 398,159,128 three years earlier.Cover page 2026-08-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRose, Snyder & Jacobs LLP, Encino, California, United StatesPCAOB Form AP 2026-04-15
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $38K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$250K$388K-$92K$186K$1.9MNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$2.2M-$342K$64K$1.8MNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed$250.4M-$783K$89K$1.7MNeeds four quarters10-Q 2026-08-13
Q3 2025
2025-09-30
Not filed-$1.0M-$307K$409KNo debt tagsNeeds four quarters10-Q 2025-11-17
Q2 2025
2025-06-30
Not filed$278K-$126K$88K$2.7MNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$299K-$167K$79K$2.6MNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$601K-$104K$86K$2.4MNeeds four quarters10-K 2026-04-15
Q3 2024
2024-09-30
Not filed-$3.3M-$143K$149K$2.4MNeeds four quarters10-Q 2025-11-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-12-23
Latest annual report10-K2026-04-15
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-10-26
Latest proxyDEF 14A2020-06-25

Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier